NXGLW — NEXGEL, Inc.

Summary of NEXGEL (NXGLW) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• NEXGEL announced the closing of its acquisition of Celularity's degenerative wound segment, expected to triple annual revenue to approximately $35 million and be immediately accretive to profitability.
• The company secured $5.5 million in capital from Sequence LifeScience through convertible notes at a $0.60 conversion price, with 50% warrant coverage at a strike price of $0.80.
• The transaction structure involved a total payout of $8.3 million, including $5.3 million paid at closing and $2.9 million owed to sales representatives.

2. Strategic Updates and Business Highlights

• Formation of a new division, BioNX Surgical, focused on advanced biomaterials for various medical applications, including wound care.
• The acquisition includes six established regenerative biomaterial products and three additional devices in the pipeline, with expected launches in 2026, 2027, and 2028.
• NEXGEL aims to leverage the experienced team from Celularity to enhance its internal capabilities in product development and marketing.
• The company is focused on integrating the new assets and driving commercial growth, emphasizing execution and sustained long-term profitability.

3. Forward Guidance and Outlook

• NEXGEL anticipates achieving EBITDA profitability by Q3 2026, with a projected contribution margin of approximately 52% from the new products.
• The company expects a recovery in Q1 2026 following a disappointing Q4 2025, with hopes to return to normal sales levels, particularly in consumer products.
• Management expressed confidence in reaching revenue levels similar to those achieved by Celularity in 2024, potentially exceeding $50 million in the next two years.

4. Bad News, Challenges, or Points of Concern

• Q4 2025 results were below expectations, attributed to underperformance of new products and setbacks in the consumer segment.
• The company faces integration challenges and potential restructuring costs, although management indicated that the transition should be relatively seamless due to the existing structure of Celularity's segment.
• There is a risk associated with the convertible notes, as failure to maintain profitability could lead to unfavorable outcomes if the notes do not convert.

5. Notable Q&A Insights

• Management clarified the structure of the acquisition deal and the terms of the convertible note, which has an 18-month maturity and a 10% coupon.
• The company will not pay royalties on most acquired products, except for specific projects with Celularity, which have low single-digit royalties.
• NEXGEL plans to utilize its new sales force to commercialize both acquired products and its existing medical devices, enhancing overall market reach.
• Management acknowledged the need for a strong sales strategy to reinvigorate sales in hospitals where the acquired products are already approved but underutilized.
• The potential for stock buybacks was discussed, contingent on achieving solid financial footing and generating cash flow.

Overall, NEXGEL's acquisition of Celularity's assets represents a significant strategic shift towards a more diversified medical technology company, with a focus on regenerative medicine and enhanced profitability. However, the company must navigate integration challenges and ensure effective sales execution to realize its growth potential.